Clinical pharmacokinetics of ciprofloxacin in patients with major burns

European Journal of Clinical Pharmacology

Volumn 55, Issue 7, 1999, Pages 515-519

  Lesne Hulin, A ^a   Bourget, P ^c   Ravat, F ^b   Goudin, C ^c   Latarjet, J ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Burn patients; Ciprofloxacin; Pharmacokinetics

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; METRONIDAZOLE; PIPERACILLIN; TICARCILLIN; VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BURN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ENTEROBACTERIACEAE; FEMALE; GRAM POSITIVE COCCI; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; WOUND INFECTION;

ADULT; AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BURNS; CIPROFLOXACIN; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0032830523     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050666     Document Type: Article

References (25)

1. Bloedow D, Hansbrough J, Hardin T, Simons M (1986) Postburn serum drug binding and serum protein concentrations. J Clin Pharmacol 26: 147-151
2. Jaehde U, Sörgel F (1995) Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 29: 15-28
3. Lesne-Hulin A, Bourget P, Carsin H (1995) Pharmacokinetics of antimicrobial agents in burn patients. Therapie 50: 575-586
4. Martyn JAJ (1986) Clinical pharmacology and drug therapy in the burned patient. Anesthesiology 65: 67-75
5. Bauerfeind A, Petermüller C (1983) In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 2: 111-113
6. Gerding DN, Hitt JA (1989) Tissue penetration of the new quinolones in humans. Rev Infect Dis 11: 1046-1057
7. Potel G, Meignier M, Touze MD (1987) Pharmacokinetics of pefloxacin in burn patients. Pathol Biol 35: 777-780
8. Van Der Auwera P, Martin A, Arnould JP (1988) Pharmacology of enoxacin given orally in severely burned patients. Rev Infect Dis 10: 107-108
9. Garrelts JC, Jost G, Kowalsky ST, Krol GJ, Lettieri JT (1996) Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 40: 1153-1156
10. Gau W, Ploschke HJ, Schmidt K (1988) Determination of ciprofloxacin in biological fluids by high-performance-liquid-chromatography. J Liq Chromatogr 8: 485-497
11. Rowland M, Tozer T (1980) Clinical pharmacokinetics: concept and applications. Lea and Febiger, Philadelphia
12. Bourget P, Delouis JM (1993) Methods for assessment of area under the curve in pharmacokinetic analysis. Therapie 48: 1-5
13. Yamaoka K, Nakagawa W, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547-558
14. Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071-1073
15. Colburn WA (1983) Estimating the accumulation of drugs. J Pharm Sci 72: 833-834
16. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH (1992) Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 36: 993-996
17. Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zameck RL, Haverstock DC, Reinhart HH, Echols RM, The Severe Pneumonia Study Group (1994) Treatment of severe pneumonia in hospitalized patients: results of a multi-center, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 38: 547-557
18. Sawada Y, Ohkubo T, Kudo M, Sugawara K (1993) Concentration of orally administered antimicrobial agent in burn scar tissue, granulation tissue, normal skin and serum. Burns 19: 529-530
19. Bourget P, Lesne-Hulin A, Le Reveille R, Lebever H, Carsin H (1996) Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 40: 139-145
20. Friedrich LV, White RL, Kays MB, Brundage DM, Yarbrough D (1991) Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 35: 57-61
21. Polk RE, Mayhall CG, Smith J, Hall G, Kline BJ, Swensson E, Haynes BW (1983) Gentamicin and tobramycin penetration into burn eschar. Arch Surg 118: 295-302
22. Walstad A, Aanderud L, Thurmann-Nielsen E (1988) Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur J Clin Pharmacol 35: 543-549
23. Zaske D, Sawchuk R, Strate R (1978) The necessity of increased doses of amikacin in burn patients. Surgery 84: 603-607
24. Antibiogram Committee of the French Society for Microbiology (1997) Statement. Pathol Biol 45: I-XII
25. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ (1993) Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 37: 1065-1072